Showing 11 of 11 posts with this tag
Phil Rivers Tech has raised an eight-figure Series A1 round to accelerate AI4S-powered drug discovery and push multiple innovative therapies into clinical development.
Deep Intelligent Pharma (DIP) secures nearly US$50 million in Series D funding to accelerate its AI-driven transformation of the entire clinical trial lifecycle.
Sinotau Pharmaceutical Group announced in a document on Thursday that it has completed a D+ round of financing worth 320 million yuan ($50.03 million). The funds raised are for clinical R&D of new radioactive drugs.
A final list of drugs to be included in China's public health insurance scheme was released on January 18. A total of 111 drugs had been added to the catalogue, and that three drugs had been dropped.
At the HUAWEI CONNECT 2022, Ken Hu, Rotating and Acting Chairman of Huawei, delivered a keynote titled "Unleash Digital," where he talked about how the company is helping organizations make the most of cloud technology to leapfrog their developments.
On the evening of December 13, Fosun Pharma, the exclusive commercial partner of Chinese COVID-19 oral drug Azvudine, confirmed that the pills can soon be prescribed through online medical platforms.
On Tuesday, Chinese 3D printing pharmaceutical company Triastek announced the completion of several hundred million yuan in a B+ round of financing.
The stock price of Yiling Pharmaceutical plunged after Wang Sicong, director of Wanda Group, reposted a video on Weibo that questioned whether the WHO had ever recommended the firm’s drug as Covid-19 treatment.
Yunnan Baiyao Group, a Chinese medicine developer and manufacturer, announced on July 25 its signing of the "Comprehensive Cooperation Agreement on Artificial Intelligence Drug R&D," alongside Shenzhen-based tech giant Huawei.
AI pharmaceutical company Galixir announced on Dec. 29 the completion of its latest two financing rounds, the Series A and Series A+, together worth tens of millions of dollars.
Junshi Biosciences, a Chinese biopharmaceutical company, announced on January 18 that the country's medical products authorities had accepted a new drug application for Deuremidevir Hydrobromide Tablets (project code: JT001/VV116) for the treatment of COVID-19.